调中益肺方联合西药治疗咳嗽变异性哮喘缓解期临床观察

摘要

Objective To observe the clinical efficacy ofTiaozhong YifeiPrescription combined with Western therapy for treatment of cough variant asthma (CVA) remission. Methods Totally 90 patients with CVA remission were randomly divided into TCM group, Western therapy group and TCM and Western therapy group, 30 cases in each group. TCM group was givenTiaozhong YifeiPrescription, 1 dose per day, morning and evening; Western therapy group was given salmeterol xinafoate and fluticasone propionate powder for inhalation, each 1 suction, 2 times a day, inhalation; a mixture ofTiaozhong YifeiPrescription and xinafoate and fluticasone propionate powder for inhalation was given to TCM and Western therapy group, the same as above, continuous treatment for 12 weeks. TCM syndrome score, EOS, IgE, pulmonary function and safety index were observed in the three groups before and after treatment. The recurrence rate and the number of colds after three-month treatment were observed.Results TCM syndrome scores in the three groups decreased after treatment (P<0.05). There was statistical significance between TCM group and TCM and Western therapy group after treatment (P<0.05). The total effective rate of TCM group was 96.67% (29/30), 100.00% (30/30) of Western therapy group, 76.67% (23/30) of TCM and Western therapy group, with statistical significance (P<0.05). After three-month treatment, 1, 0 and 11 cases relapsed in TCM group, TCM and Western therapy group and Western therapy group, respectively, with statistical significance (P<0.001). Compared with the Western therapy group, the number of colds in the TCM group and TCM and Western therapy group significantly decreased (P<0.05). Compared with before treatment, IgE decreased significantly (P<0.05). There was no significant difference in EOS among the three groups before and after treatment (P>0.05). After treatment, the maximum expiratory flow in TCM and Western therapy groupwas higher than that before treatment and lower than that in the Western therapy group (P<0.01), and the other lung function indexes were not statistically significant (P>0.05). 1 mild adverse reaction was found in the TCM and Western therapy, and no obvious adverse reactions were found in other groups (P<0.05).ConclusionTiaozhong Yifei Prescription has good clinical efficacy for CVA.%目的 观察调中益肺方联合西药对脾肺不足、气阴两虚型咳嗽变异性哮喘(CVA)缓解期的临床疗效.方法 将90例CVA缓解期患者随机分为中药组、西药组、中西组各30例.中药组予调中益肺方,每日1剂,早晚分服;西药组给予沙美特罗替卡松粉吸入剂,每次1吸,每日2次,吸入;中西组予调中益肺方合沙美特罗替卡松粉吸入剂,用法同上.连续治疗12周.观察3组治疗前后中医症状积分及中医疗效、治疗后3个月的复发率和感冒次数、外周血嗜酸性粒细胞计数(EOS)、IgE、肺功能及安全性指标.结果 治疗后3组中医症状积分均降低(P<0.05);治疗后中药组、中西组与西药组比较差异有统计学意义(P<0.05).中药组中医疗效总有效率为96.67%(29/30),中西组为100.00%(30/30),与西药组76.67%(23/30)比较,差异有统计学意义(P<0.05).治疗后3个月,中药组、中西组、西药组分别复发1、0、11例,差异有统计学意义(P<0.001);与西药组比较,中药组、中西组感冒次数明显减少(P<0.05).与治疗前比较,中西组IgE下降明显(P<0.05);3组EOS治疗前后组内、组间比较差异均无统计学意义(P>0.05).中西组最大呼气流量较治疗前提高,治疗后与西药组比较差异有统计学意义(P<0.01),其余肺功能指标比较差异无统计学意义(P>0.05).中西组轻度不良反应1例,其余未见明显不良反应.结论 调中益肺方治疗CVA具有较好的临床疗效.